Table 3. Among the seven cytokines significantly correlating with DFS in the training cohort, six of them were consistently validated in the validation cohort.
| |
Training cohort |
Validation cohort |
||||
|---|---|---|---|---|---|---|
| Cytokine (pg ml−1) | Patients, n | 2-year DFS rate (%) | P-value | Patients, n | 2-year DFS rate (%) | P-value |
|
FGF-2 |
|
|
0.037 |
|
|
0.026 |
| ⩽9.66 | 31 | 54.8 | 26 | 53.8 | ||
| >9.66 |
72 |
22.2 |
|
50 |
32.0 |
|
|
IFN-α2 |
|
|
0.001 |
|
|
0.014 |
| ⩽4.425 | 79 | 24.1 | 42 | 26.2 | ||
| >4.425 |
24 |
58.3 |
|
34 |
55.9 |
|
|
GRO |
|
|
<0.001 |
|
|
0.018 |
| ⩽548.5 | 86 | 37.2 | 39 | 53.8 | ||
| ⩾548.5 |
17 |
5.9 |
|
37 |
24.3 |
|
|
IL-8 |
|
|
0.004 |
|
|
0.002 |
| ⩽18.93 | 66 | 42.4 | 38 | 57.9 | ||
| >18.93 |
37 |
13.5 |
|
38 |
21.1 |
|
|
IP-10 |
|
|
0.012 |
|
|
0.014 |
| ⩽223.5 | 42 | 50.0 | 50 | 48.0 | ||
| >223.5 |
61 |
19.7 |
|
26 |
23.1 |
|
|
MIP1β |
|
|
0.022 |
|
|
0.520 |
| ⩽25.35 | 64 | 25.0 | 46 | 41.3 | ||
| >25.35 |
39 |
43.6 |
|
30 |
36.7 |
|
|
VEGF |
|
|
0.001 |
|
|
0.004 |
| ⩽151 | 80 | 37.5 | 59 | 49.2 | ||
| >151 | 23 | 13.0 | 17 | 5.9 | ||
Abbreviations: DFS=disease-free survival; FGF-2=fibroblast growth factor 2; GRO=growth-regulated oncogene; IFN-α2=interferon alpha-2; IL-8=interleukin 8; IP-10=interferon gamma-induced protein 10; VEGF=vascular endothelial growth factor.